It compounded earnings per share at 15.5% a year for a decade. It was never cheap. Then it halved in sixteen months — with a 70.9% gross margin and a 21.6% return on invested capital fully intact.
This is the thing every patient investor claims to be waiting for, and this is what it actually looks like when it arrives: guidance cut twice in a year, earnings guided to fall, and a very good reason for everybody else to be selling.
It never arrives looking like a bargain. If it did, it would not be one.
Most of the fall was not about earnings at all
| Then | At our report | Effect | |
|---|---|---|---|
| Multiple | Mid-thirties | 12.7× | −64% from the rating alone |
| Gross margin | ~71% | 70.9% | Unchanged |
| Return on invested capital | High | 21.6% | Unchanged |
| Free cash flow yield | Low | 7.3% | The inverse of 13.7× cash |
| Guidance | Rising | Cut twice; earnings to fall | The reason for all of the above |
Read the first row against the next three. The business did not deteriorate by 64%. The market's willingness to pay for it did.
That is a derating, and it is the most under-appreciated source of loss in quality investing — because nothing visible goes wrong. The company keeps performing and the shares fall anyway, because what was being paid for was certainty, and certainty was withdrawn.
A quality business priced for certainty has a very long way to fall the moment certainty is withdrawn — and it need not do anything wrong on the way down.
Two companies that look identical from here
Our July report found a business with 82% gross margins and a 66% return on equity that was down about 63%. On the numbers alone that is among the finest economics we have examined in any sector.
It fell anyway — not because the economics deteriorated, but because a rival's molecule worked better.
So now put the two side by side. Both wonderful. Both halved. One has softening demand in a structurally excellent industry; the other has lost a head-to-head contest. They look the same on a screen and they are not the same investment.
| The question | Cyclical softness | Competitive loss |
|---|---|---|
| What changed | Customers spent less this year | A rival took the position |
| Does it repair itself? | Usually, with time | Rarely, and never on its own |
| What you are betting on | Patience | Management out-executing someone better |
| The tell | Margins and returns hold | Margins may hold while share does not |
It is not purely cyclical. American pet owners have become price-sensitive, clinic visits are falling, and two competitors arrived with better labels on the two biggest franchises. That last one is competitive, not cyclical.
What argues the other way is the structure of the industry itself: no insurer negotiating the price down, no patent cliff of the human-pharmaceutical kind, a customer who pays cash because the dog is family, and a distribution channel of veterinarians who are hard to reach and harder to replace.
The industry's advantages are intact. The company's share of them is being contested. That is a genuine argument on both sides, and anyone telling you it is obvious has not read the filings.
Right about the business, three weeks late
Our PayPal report found it 82% below its 2021 peak and concluded it was cheap, and genuinely not a trap — and that the bargain had got away three weeks earlier.
That is worth sitting with, because it is the most common outcome of all. Not wrong about the company. Not wrong about the value. Just not there when the price was. A wonderful business is cheap for a window, and the window is usually measured in weeks.
How to be ready instead of right
Decide what you would pay for the business while you still admire it and nothing is wrong. A number written calmly survives the moment the guidance is cut; a number worked out during the fall will be reverse-engineered from the quote in front of you.
Two columns. Gross margin, return on capital, cash conversion in one; market share, win rates, head-to-head results in the other. The first column holding while the second slips is the warning that this is not a cycle.
There is no version of this where a 12.7× multiple on a wonderful business coexists with rising guidance. If you require the news to improve first, you will buy after the rerating, which is the same as not buying at all.
Nobody catches the bottom. Assume you are three weeks or six months early and choose a size that makes that survivable — a position you can add to is worth more than one you have to defend.
A 7.3% free cash flow yield is the inverse of 13.7 times cash. Set against a Treasury paying 5.12%, you are being offered a 2.2 point premium — from a business earning 21.6% on its invested capital.
That is not a screaming bargain and it is not supposed to be. It is what a genuinely excellent business looks like when the market has stopped assuming the next decade. Whether it is enough depends on something no ratio contains: whether the vets keep prescribing it.
A quality business derated 64%, one whose economics held while it lost a trial, and one where the bargain closed before we wrote.
Including what we found about the product at the centre of the noise.
Frequently asked
Why do high-quality stocks fall so far?
Because the multiple does most of the work. Zoetis went from the mid-thirties times earnings to 12.7 — a 64% derating. Even if earnings had been perfectly flat, that alone would have more than halved the shares. A quality business priced for certainty has a very long way to fall the moment certainty is withdrawn, and the business itself need not change much.
How do you tell quality that is temporarily cheap from quality that is broken?
Separate the economics from the position. Zoetis still earned a 70.9% gross margin and 21.6% on invested capital while guidance was cut twice — the machine works, the demand softened. Novo Nordisk kept 82% gross margins and a 66% return on equity while falling 63%, because a rival's molecule worked better. The first is a cycle; the second is a competitive loss, and only one of them repairs itself.
Should you buy when earnings are guided to fall?
That is usually the only time the price is available. A wonderful business trading cheaply while results are still rising is rare to the point of non-existence — the discount exists precisely because the near term looks bad. The discipline is to decide in advance what would have to stay true, then check whether it has, rather than waiting for the news to improve first.
What is a derating?
A fall in the multiple investors will pay for the same earnings. It is the most under-appreciated source of loss in quality investing, because nothing goes wrong operationally — the company delivers, and the shares fall anyway because the market has changed its mind about how certain the future is.